In an industry defined by bold ideas and even bolder challenges, Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden the commercial and therapeutic prospects of its lead candidate, EB-003 — a compound designed to drive neuroplasticity without the hallucinogenic liabilities of classic psychedelics.
